STRIDES PHARMA supplier risk Q1-2026: India-focused pharma import footprint, 90 shipments, 7 suppliers.
STRIDES PHARMA imported 90 shipments in Q1 2026 across 7 suppliers sourced from 2 countries. India accounted for 99% of shipments, with STRIDES PHARMA SCIENCE providing 81 of the 90 total incoming shipments. The importer's trade is concentrated in HS Chapter 30 (pharmaceutical products), with activity across a single HS code. A secondary India-based supplier, ONESOURCE SPECIALTY PHARMA, contributed 3 shipments.
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
STRIDES PHARMA registered zero sanctions watchlist matches. No suppliers showed exposed forced-labor proximity under UFLPA risk screening. The importer's overall risk grade is B, with a total score of 71.
7 distinct tier-1 suppliers in Q1 2026
| STRIDES PHARMA SCIENCE | India | 81 |
| ONESOURCE SPECIALTY PHARMA | India | 3 |
| BUDHRAJA PACKAGING | India | 2 |
| STRIDES PHARMA SCIENCES | India | 1 |
| SOLARA ACTIVE PHARMA SCIENCES LIMIT | India | 1 |
| ONEOSURCE SPECILATY PHARMA | India | 1 |
| STRIDES PHARMA | Singapore | 1 |
Share of Q1 2026 inbound shipments by source country
5 tier-2 + 5 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.